NEJM:单次口服Zoliflodacin可有效治疗淋病

2018-11-15 zhangfan MedSci原创

研究认为口服Zoliflodacin可治愈大多数非复杂的泌尿生殖道和直肠淋球菌感染,但其对咽部感染的治疗效果不佳

耐药性淋病奈瑟菌(Neisseria淋病)的治疗是非复杂淋病治疗的新挑战,近日研究人员考察了口服新型细菌DNA促旋酶/拓扑异构酶抑制剂对Neisseria淋病的治疗效果。

Neisseria淋病男女患者参与研究,随机接受单剂量Zoliflodacin (2或3 g)口服或500mg头孢曲松注射。平均治疗后6天进行治愈试验,治疗后31天进行安全随访,主要终点为治愈率。

179名患者参与研究,其中男性167人,141人接受疗效评估,其中57人接受2g 的Zoliflodacin治疗,56人接受3g治疗,28人接受头孢曲松。各组治愈率分别为96%、96%和100%,存在直肠感染人群也均得到治愈,咽感染治愈率分别为50%、82%和100%。总计发生84起不良事件,各组分别发生24、33和23起,其中21起不良事件与Zoliflodacin相关,多为肠道事件。

研究认为口服Zoliflodacin可治愈大多数非复杂的泌尿生殖道和直肠淋球菌感染,但其对咽部感染的治疗效果不佳。

原始出处:

Stephanie N. Taylor et al. Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea.N Engl J Med, November 15, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=899251, encodeId=7ac08992518e, content=<a href='/topic/show?id=583b6604629' target=_blank style='color:#2F92EE;'>#淋病#</a>新型抗生素, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66046, encryptionId=583b6604629, topicName=淋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Nov 15 09:20:28 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773746, encodeId=a2381e73746c9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jun 16 15:50:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355950, encodeId=2e13355950d1, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Dec 20 18:40:27 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353470, encodeId=d5ad3534e070, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 23 19:04:08 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619529, encodeId=0813161952947, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 17 00:50:00 CST 2018, time=2018-11-17, status=1, ipAttribution=)]
    2020-11-15 lovetcm

    #淋病#新型抗生素

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=899251, encodeId=7ac08992518e, content=<a href='/topic/show?id=583b6604629' target=_blank style='color:#2F92EE;'>#淋病#</a>新型抗生素, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66046, encryptionId=583b6604629, topicName=淋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Nov 15 09:20:28 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773746, encodeId=a2381e73746c9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jun 16 15:50:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355950, encodeId=2e13355950d1, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Dec 20 18:40:27 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353470, encodeId=d5ad3534e070, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 23 19:04:08 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619529, encodeId=0813161952947, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 17 00:50:00 CST 2018, time=2018-11-17, status=1, ipAttribution=)]
    2019-06-16 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=899251, encodeId=7ac08992518e, content=<a href='/topic/show?id=583b6604629' target=_blank style='color:#2F92EE;'>#淋病#</a>新型抗生素, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66046, encryptionId=583b6604629, topicName=淋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Nov 15 09:20:28 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773746, encodeId=a2381e73746c9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jun 16 15:50:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355950, encodeId=2e13355950d1, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Dec 20 18:40:27 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353470, encodeId=d5ad3534e070, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 23 19:04:08 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619529, encodeId=0813161952947, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 17 00:50:00 CST 2018, time=2018-11-17, status=1, ipAttribution=)]
    2018-12-20 wxl882001

    了解一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=899251, encodeId=7ac08992518e, content=<a href='/topic/show?id=583b6604629' target=_blank style='color:#2F92EE;'>#淋病#</a>新型抗生素, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66046, encryptionId=583b6604629, topicName=淋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Nov 15 09:20:28 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773746, encodeId=a2381e73746c9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jun 16 15:50:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355950, encodeId=2e13355950d1, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Dec 20 18:40:27 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353470, encodeId=d5ad3534e070, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 23 19:04:08 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619529, encodeId=0813161952947, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 17 00:50:00 CST 2018, time=2018-11-17, status=1, ipAttribution=)]
    2018-11-23 wxl882001

    学习一下

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=899251, encodeId=7ac08992518e, content=<a href='/topic/show?id=583b6604629' target=_blank style='color:#2F92EE;'>#淋病#</a>新型抗生素, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66046, encryptionId=583b6604629, topicName=淋病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Sun Nov 15 09:20:28 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773746, encodeId=a2381e73746c9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jun 16 15:50:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355950, encodeId=2e13355950d1, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Dec 20 18:40:27 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353470, encodeId=d5ad3534e070, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 23 19:04:08 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619529, encodeId=0813161952947, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sat Nov 17 00:50:00 CST 2018, time=2018-11-17, status=1, ipAttribution=)]

相关资讯

抗生素耐药竟然影响淋病的治疗!

世界卫生组织(WHO)警告,抗生素耐药性使得淋病更难治,甚至有时候是无法治疗的。

2012欧洲指南——成人淋病的诊断和治疗发布

淋病是一个全球主要公共卫生问题,在2009版欧洲淋病指南的基础上,2012版指南主要针对淋病的检测和治疗,引入双重抗菌治疗等方面提供最新指导建议。目的是优化淋病的检测,诊断,抗菌治疗以及随访等。全文获取:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积分下载)

PLoS Med:WHO严重警告:“超级淋病细菌”正在全球扩散,已接近无药可医

性传播疾病正在慢慢变得失控!最近,世界卫生组织在《PLoS Medicine》特刊中提出了很严重的警告,认为随着病菌耐药性的提升,绝大部分的抗生素药物将完全失效,这将导致以淋病为代表的性传染病将变得不可治愈。也正因如此,开发出新型的治疗药物在当下已经变的迫在眉睫。

Lancet:乙脑疫苗或能对抗超级淋病

一种针对乙型脑膜炎的疫苗或能阻止耐抗生素的超级淋病的扩散。

新型抗生素有助应对淋病

伦敦大学卫生和热带医学院发布的一项最新研究显示,一种新型抗生素在实验室环境下显示了对淋球菌的有效抑制作用,鉴于淋球菌耐药问题日益突出,未来有望基于这一发现开发新的治疗药物。

Lancet:B群脑膜炎球菌外膜囊胞疫苗预防淋病的效果。

淋病是一主要的全球性公共健康问题,因耐药性而更加棘手。开发有效的疫苗尚未成功,但监测数据提示B群脑膜炎球菌外膜囊胞疫苗会影响淋病的发病率。研究人员对在新西兰15-30岁人群中脑膜炎球菌外膜囊胞B疫苗(MeNZB)抗淋病的效果进行评估。